ARTICLE | Company News
MedImmune to divest CytoGam
November 9, 2006 1:48 AM UTC
CSL (ASX:CSL) will acquire MEDI's CytoGam cytomegalovirus immune globulin to prevent cytomegalovirus (CMV) disease associated with transplantation. MEDI, which said CytoGam no longer fits into its cor...